166 related articles for article (PubMed ID: 38800557)
1. Precision genome editing offers hope for treatment of β-thalassemia and other genetic disorders.
Abbas Z; Rahman A; Aslam B; Aftab S; Feng C; Baloch Z
Mol Ther Nucleic Acids; 2024 Jun; 35(2):102204. PubMed ID: 38800557
[No Abstract] [Full Text] [Related]
2. Prime editing: A potential treatment option for β-thalassemia.
Arif T; Farooq A; Ahmad FJ; Akhtar M; Choudhery MS
Cell Biol Int; 2023 Apr; 47(4):699-713. PubMed ID: 36480796
[TBL] [Abstract][Full Text] [Related]
3. Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies.
Paschoudi K; Yannaki E; Psatha N
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298481
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia.
Zeng S; Lei S; Qu C; Wang Y; Teng S; Huang P
Hum Genet; 2023 Dec; 142(12):1677-1703. PubMed ID: 37878144
[TBL] [Abstract][Full Text] [Related]
5. Combined approaches for increasing fetal hemoglobin (HbF) and
Finotti A; Gambari R
Front Genome Ed; 2023; 5():1204536. PubMed ID: 37529398
[TBL] [Abstract][Full Text] [Related]
6. [Advances in gene therapy for β-thalassemia and hemophilia based on the CRISPR/Cas9 technology].
Bao LW; Zhou YY; Zeng FY
Yi Chuan; 2020 Oct; 42(10):949-964. PubMed ID: 33229321
[TBL] [Abstract][Full Text] [Related]
7. Advances in genome editing: the technology of choice for precise and efficient β-thalassemia treatment.
Ali G; Tariq MA; Shahid K; Ahmad FJ; Akram J
Gene Ther; 2021 Feb; 28(1-2):6-15. PubMed ID: 32355226
[TBL] [Abstract][Full Text] [Related]
8. Gene Therapy and Gene Editing for β-Thalassemia.
Christakopoulos GE; Telange R; Yen J; Weiss MJ
Hematol Oncol Clin North Am; 2023 Apr; 37(2):433-447. PubMed ID: 36907613
[TBL] [Abstract][Full Text] [Related]
9. Co-Treatment of Erythroid Cells from β-Thalassemia Patients with CRISPR-Cas9-Based β
Cosenza LC; Zuccato C; Zurlo M; Gambari R; Finotti A
Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292612
[TBL] [Abstract][Full Text] [Related]
10. Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease.
Khosravi MA; Abbasalipour M; Concordet JP; Berg JV; Zeinali S; Arashkia A; Azadmanesh K; Buch T; Karimipoor M
Eur J Pharmacol; 2019 Jul; 854():398-405. PubMed ID: 31039344
[TBL] [Abstract][Full Text] [Related]
11. Efficient CRISPR-Cas9-based genome editing of β-globin gene on erythroid cells from homozygous β
Cosenza LC; Gasparello J; Romanini N; Zurlo M; Zuccato C; Gambari R; Finotti A
Mol Ther Methods Clin Dev; 2021 Jun; 21():507-523. PubMed ID: 33997100
[TBL] [Abstract][Full Text] [Related]
12. Induction of Fetal Hemoglobin by Introducing Natural Hereditary Persistence of Fetal Hemoglobin Mutations in the γ-Globin Gene Promoters for Genome Editing Therapies for β-Thalassemia.
Lu D; Xu Z; Peng Z; Yang Y; Song B; Xiong Z; Ma Z; Guan H; Chen B; Nakamura Y; Zeng J; Liu N; Sun X; Chen D
Front Genet; 2022; 13():881937. PubMed ID: 35656314
[TBL] [Abstract][Full Text] [Related]
13. [Regulation of γ-globin gene expression and its clinical applications].
Ju JY; Zhao Q
Yi Chuan; 2018 Jun; 40(6):429-444. PubMed ID: 29959116
[TBL] [Abstract][Full Text] [Related]
14. New Frontiers: Precise Editing of Allergen Genes Using CRISPR.
Brackett NF; Pomés A; Chapman MD
Front Allergy; 2021; 2():821107. PubMed ID: 35386981
[TBL] [Abstract][Full Text] [Related]
15. Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemia.
Mettananda S; Fisher CA; Hay D; Badat M; Quek L; Clark K; Hublitz P; Downes D; Kerry J; Gosden M; Telenius J; Sloane-Stanley JA; Faustino P; Coelho A; Doondeea J; Usukhbayar B; Sopp P; Sharpe JA; Hughes JR; Vyas P; Gibbons RJ; Higgs DR
Nat Commun; 2017 Sep; 8(1):424. PubMed ID: 28871148
[TBL] [Abstract][Full Text] [Related]
16. Design Principles of a Novel Construct for HBB Gene-Editing and Investigation of Its Gene-Targeting Efficiency in HEK293 Cells.
Lotfi M; Ashouri A; Mojarrad M; Mozaffari-Jovin S; Abbaszadegan MR
Mol Biotechnol; 2024 Mar; 66(3):517-530. PubMed ID: 37266832
[TBL] [Abstract][Full Text] [Related]
17. Context base editing for splice correction of IVSI-110 β-thalassemia.
Naiisseh B; Papasavva PL; Papaioannou NY; Tomazou M; Koniali L; Felekis X; Constantinou CG; Sitarou M; Christou S; Kleanthous M; Lederer CW; Patsali P
Mol Ther Nucleic Acids; 2024 Jun; 35(2):102183. PubMed ID: 38706633
[TBL] [Abstract][Full Text] [Related]
18. Comparison of capillary electrophoregram among heterozygous Hb Hope, Hb Hope/α-thalassemia-1 SEA type deletion and Hb Hope/β(0)-thalassemia.
Pornprasert S; Panyasai S; Kongthai K
Clin Chem Lab Med; 2012 Mar; 50(9):1625-9. PubMed ID: 22962223
[TBL] [Abstract][Full Text] [Related]
19. Correction of Beta-Thalassemia IVS-II-654 Mutation in a Mouse Model Using Prime Editing.
Zhang H; Sun R; Fei J; Chen H; Lu D
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682629
[TBL] [Abstract][Full Text] [Related]
20. Site-specific genome editing in treatment of inherited diseases: possibility, progress, and perspectives.
Huang C; Li Q; Li J
Med Rev (2021); 2022 Oct; 2(5):471-500. PubMed ID: 37724161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
